The course of haemolytic anaemia in NZB mice has been altered by injection of spleen cells from diseased mice into younger ones before the onset of clinical disease. Recipients greater than 6 weeks of age developed early-onset autoimmune disease, recipients less than 6 weeks of age developed early-onset autoimmune disease, recipients less than 6 weeks of age recovered from early induced disease and showed a delay in the onset of spontaneous disease as compared with untreated NZB mice. This delay was due to the induction in the young mice of splenic suppressor cells. These cells were non-adherent to nylon wool and suppressed autoantibody formation on transfer to old Coombs-positive recipients. Suppressor cells active against autoantibody formation on transfer to old Coombs-positive recipients. Suppressor cells active against autoantibody-producing cells may be present in young untreated NZB mice, but not in sufficient numbers to suppress autoantibody production on adoptive transfer to Coombs-positive; however, when Ig-negative cells from the spleens of very young NZB mice were transferred together with Ig-positive cells from Coombs-positive donor mice to irradiated NZB recipients, the autoantibody production of the transferred B cells was suppressed in some cases. Suppressor cell activity could also be induced by co-culture of spleen cells from old Coombs-positive and young Coombs-negative NZB mice in vitro.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1537400PMC

Publication Analysis

Top Keywords

nzb mice
24
suppressor cells
16
disease recipients
12
weeks age
12
transfer coombs-positive
12
cells
11
mice
9
haemolytic anaemia
8
anaemia nzb
8
spleen cells
8

Similar Publications

Article Synopsis
  • Mitochondrial dysfunction and macrophage dysregulation are important in autoimmune diseases, but how they connect is not fully understood.
  • The study focuses on the role of chronic low-level interferon-gamma (IFN-γ) using a mouse model with lupus-like symptoms, finding that this condition suppresses mitochondrial function, especially in the kidneys.
  • It suggests that restoring mitochondrial function could improve macrophage activity and provide new targets for treating autoimmune diseases like lupus nephritis.
View Article and Find Full Text PDF

Mitochondrial DNA (mtDNA) is highly polymorphic, and host mtDNA variation has been associated with altered cancer severity. To determine the basis of this mtDNA-cancer association, we analyzed conplastic mice with the C57BL/6J (B6) nucleus but two naturally occurring mtDNA lineages, and , where mitochondria generate more oxidative phosphorylation (OXPHOS)-derived reactive oxygen species (mROS). In a cardiac transplant model, Foxp3+ T regulatory (Treg) cells supported long-term allograft survival, whereas Treg cells failed to suppress host T effector (Teff) cells, leading to acute rejection.

View Article and Find Full Text PDF
Article Synopsis
  • * In studies using a mouse model lacking the NPC1 protein in immune cells, researchers found significant changes in microglial lipid profiles, increased microglial activity, and symptoms resembling NPC disease, such as lifespan reduction and motor issues.
  • * Monitoring translocator protein (TSPO) levels in the blood may be useful for assessing NPC disease progression and treatment response, as shown by changes in TSPO levels following a specific therapy that appeared beneficial for patients.
View Article and Find Full Text PDF

Therapeutic effects of extracellular vesicles derived from mesenchymal stem cells primed with disease-conditioned-immune cells in systemic lupus erythematosus.

Arthritis Res Ther

November 2024

GenNBio Inc, 80, Deurimsandan 2-ro, Cheongbuk-eup, Pyeongtaek-si, Gyeonggi-do, 17796, Republic of Korea.

Article Synopsis
  • Systemic lupus erythematosus (SLE) is a chronic, incurable autoimmune disease, prompting the need for effective treatments, such as using extracellular vesicles (EV) from mesenchymal stem cells (iMSCs) primed with immune cell media.
  • In the study, female NZB/W F1 mice were divided into three groups to assess the effects of CM-EV and ASC-EV treatments compared to a control group, with assessment done over 36 weeks.
  • Results showed that CM-EV treatment enhanced survival rates, reduced harmful antibodies, and improved kidney health, while both EV types decreased pro-inflammatory macrophages, indicating their potential in modulating SLE’s immune response.
View Article and Find Full Text PDF

Neuropilin-1 as a Key Molecule for Renal Recovery in Lupus Nephritis: Insights from an NZB/W F1 Mouse Model.

Int J Mol Sci

October 2024

Rheumatology Research Group-Lupus Unit, Vall d'Hebrón University Hospital, Vall d'Hebrón Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.

Article Synopsis
  • - Systemic lupus erythematosus (SLE) is an autoimmune disease affecting many organs, with lupus nephritis (LN) impacting 40-50% of patients and potentially leading to serious kidney complications like end-stage renal disease (ESRD).
  • - This study investigates the role of neuropilin-1 (NRP-1), a receptor in kidney tissue, as a biomarker for kidney recovery in LN using a mouse model, demonstrating a significant increase in NRP-1 levels over time.
  • - High urinary NRP-1 levels (above 34.40 ng/mL) were strongly associated with positive renal outcomes, highlighting NRP-1's potential as a reliable biomarker for kidney recovery in
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!